Black Cohosh (Actaea racemosa syn. Cimicifuga racemosa)
Exercise
Bone Mineral Density
Coronary Heart Disease
Menopause
Date: 06-15-2010
HC# 051051-402
Re: The Surprising Effects of Intensity of Exercise and Black Cohosh on Coronary Heart Disease Risk and Bone Density
Bebenek M, Kemmler W, von Stengel S, Engelke K, Kalender WA. Effect of exercise and Cimicifuga racemosa (CR BNO 1055) on bone mineral density, 10-year coronary heart disease risk, and menopausal complaints: the randomized controlled Training and Cimicifuga racemosa Erlangen study. Menopause. March 18, 2010. [Epub ahead of print] doi: 10.1097/gme.0b013e3181cc4a00.
During
early post-menopause, estrogen depletion causes women to have a change in body
composition, menopausal symptoms, accelerated bone loss, and a change in fat
distribution. Aside from hormone replacement therapy (HRT), exercise is
considered an effective approach to counteracting the effects of estrogen
depletion. Black cohosh (Actaea racemosa
syn. Cimicifuga racemosa) is an
herbal alternative to HRT. There are in vitro, in vivo, and human studies that
demonstrate a positive synergistic effect of exercise and estrogen on bone.
Hence the purpose of this study was to examine the effects of a high-intensity
exercise regimen on bone and cardiovascular health, and to investigate whether
a combination of exercise and black cohosh improves the effect of exercise
alone. This study is known as the TRACE study (Training and Cimicifuga racemosaErlangen).
Patients
(aged 48-55 years) living in Erlangen-Nuremberg,
Germany, were
recruited by mail to participate in this 12-month, placebo-controlled, randomized
study. Included women were 1-3 years post-menopause, were not using any
medication that would affect study endpoints, had no history of stroke or
cardiac events, had no secondary osteoporosis, and had no athletic history.
Women (n = 128) were stratified by age, and randomized to 1 of 3 treatment
groups: (1) exercise = a complex high-intensity aerobic and resistance exercise
program that focused primarily on bone strength, plus placebo (n = 43), (2)
exercise as described above and 40 mg/day black cohosh (CR BNO 1055; Bionorica;
Neumarkt, Germany) (n = 43), and (3) wellness control = program with low training
frequency and intensity (i.e., walking, balance, flexibility) that focused on
well-being (n = 42). The exercise program focused on bone parameters for the
first 6 weeks and then cardiovascular parameters the second 6 weeks, in an
alternating pattern for 1 year. The black cohosh dosage was as per the
manufacturer’s recommendation; specifically, 3 months of intake followed by 3
months abstaining from use, followed by 3 months of intake, and so forth. All
participants received calcium (1,500 mg/d) and cholecalciferol (vitamin D,
500 IE/d) supplements (Opfermann; Wiehl,
Germany). The
primary efficacy variables were bone mineral density (lumbar spine and proximal
hip) and the 10-year coronary heart disease (CHD) risk according to Wilson et al.1 The
secondary endpoints were menopausal symptoms, body composition, and aerobic
capacity. Measurements were taken at baseline and 12 months.
There were
7 patients in the exercise group, 6 patients in the black cohosh/exercise group,
and 12 participants in the control group who were lost to follow-up. None of
the discontinuations were due to adverse events. At baseline, there was no
difference between groups on any measurement. Compliance with black cohosh
treatment and calcium/vitamin D supplementation was high. Exercise attendance
was 65% for both groups. The groups were successfully blinded, with 77% of the
patients in the black cohosh group believing that they were in the placebo
group.
At the
lumbar spine, bone mineral density was maintained in both exercise groups, but
significantly decreased in the control group (P < 0.001). There was no
significant difference between the exercise and the black cohosh/exercise
groups in bone mineral density of the lumbar spine. There was no significant
change in bone mineral density of the femoral neck of any group.
The ten-year
Framingham-based risk for CHD significantly increased in the black
cohosh/exercise group by 12.9% ± 25.1% (P = 0.018), and increased by 16.5% ±
27.8% in the control group (P = 0.007). In contrast, the exercise group had
only a 2.7% ± 21.9% increase in risk.
In both
exercise groups, menopausal complaints (psychological, somato-vegetative, and urogenital
domains) significantly decreased by 20.0% ± 23.7% (P < 0.001) in the
exercise group and 20.7% ± 34.1% (P = 0.003) in the black cohosh/exercise group
compared with baseline. There was no significant change in total or abdominal
body fat in either group. Both exercise groups had a significant increase in
aerobic capacity; there was no significant difference between groups.
Contrary
to agents with selective estrogen receptor modification, black cohosh did not
enhance the positive effect of exercise on bone mass density, menopausal
symptoms, aerobic capacity, or lean body mass. However, the authors state that
an important new finding is the knowledge that it is not necessary to exercise continuously
at high loading intensities to impact bone density. The exercise intensity,
duration, and frequency should have been sufficient to impact the CHD risk
score. The authors state that the significant increase in the 10-year CHD risk
in the black cohosh/exercise group and the control group “is alarming.” They
provide no explanation for this alarming finding or for the limited improvement
in menopausal symptoms in the black cohosh/exercise group: no significant
differences were detected “concerning modifiable factors constituting … or
corresponding with … risk score between the groups.” It should be noted that
these findings are specific for women 1-3 years post-menopause. The results may
differ in a different patient population.
Two
weaknesses of the study not noted by the authors are: 1) The article states
that all patient groups received vitamin D and calcium which per se have
antiosteoporotic effects. Other published studies have found that a combination
of vitamin D and calcium was able to prevent the development of osteoporosis
significantly. Hence, a totally untreated group should have served as a negative
control. 2) The 10-year expectation of cardiovascular diseases on the basis of
the Framingham-based risk for CHD is another point of concern. Nowhere in other
literature is it stated that black cohosh increases cardiovascular risk factors
and this is substantiated by the finding that abdominal fat – the major risk
factor for CHD – was not significantly different in each of the 3 treatment
groups.
—Heather
S. Oliff, PhD
Reference
1Wilson PW, D’Agostino RB,
Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart
disease using risk factor categories. Circulation.
1998;97:1837-1847.